Infectious Diseases

The November issue covered a variety of topics on vaccination, which can help clinicians have candid conversations with colleagues, patients, and families.

Surviving a bout of cancer early in life puts children and teenagers at risk of cancers linked to human papillomavirus (HPV). A phase 2 trial examined how effective a 3-dose series was in providing protection.

The National Institutes of Health announced the launch of a long-term study into the long ranging outcomes of recovering from COVID-19 in children, adolescents, and young adults.

Paul Offit, MD, discusses the state of COVID-19 vaccines and children.

A look at the Centers for Disease Control and Prevention's (CDC) vaccination schedule for the pediatric population.

Misinformation about the disease and vaccinations remains widespread.

Not every vaccine is required, some are just strongly recommended. Here's what to know about 5 recommended vaccines.

A look at where vaccine technologies will be going.

Contemporary Pediatrics sat down with editor-in-chief Dr. Tina Q. Tan to discuss the what lies ahead in the vaccine pipeline for the pediatric population.

What we can look forward to in preventing infectious diseases.

A study examines whether an intervention that promotes including teenagers in the decision-making process for getting vaccines leads to better outcomes, such as vaccine literacy.

Best tactics for pediatricians when speaking with patients who resist immunization.

A look at vaccine registries: what they are, and why they are so crucial.

Sharing how vaccinations first began and were implemented can be a useful tool in educating families of their importance.

Ocugen, Inc. has submitted a request to the US Food and Drug Administration for emergency use authorization (EUA) for their COVID-19 vaccine candidate for use in children aged 2-18 years.

Effective vaccines are one of the greatest public health achievements. Dr. Tina Q. Tan shares how the November issue is dedicated to vaccines, from the history to tackling vaccine hesitancy.

Contemporary Pediatrics sat down with editor-in-chief Dr. Tina Q. Tan to discuss the approval of the COVID-19 vaccine for children aged 5 to 11 years and conversations with parents.

Rochelle Walensky, MD endorsed the recommendation from the members of the CDC's Advisory Committee on Immunization Practices to administer Pfizer/BioNTech's COVID-19 vaccine for children aged 5-11 years.

The US Food and Drug Administration (FDA) has amended the emergency use authorization of the Pfizer/BioNTech vaccine to include children aged 5 to 11 years.

The US Food and Drug Administration (FDA) committee voted on whether the emergency use authorization should be extended to children aged 5 to 11 years.

The US Food and Drug Administration (FDA) is meeting to discuss amending the emergency use authorization of the Pfizer/BioNTech vaccine for children aged 5 to 11 years.

Dr. Tan shares her must-reads from the October issue.

Seqirus’s FLUCELVAX® cell-based quadrivalent influenza vaccine has been approved to expand the age indication to children as young as 6 months of age by the US Food and Drug Administration.

Between the subtle differences between viral and bacterial pneumonia and the demands or beliefs of certain parents can make an accurate diagnosis of community-acquired pneumonia (CAP) more difficult.

A look at what the pandemic and its many changes meant for the education of children with disabilities, presented at the virtual 2021 American Academy of Pediatrics National Conference & Exhibition.

At the virtual 2021 American Academy of Pediatrics National Conference & Exhibition, Ibukun Kalu, MD, discussed what is known about the pathophysiology of multisystem inflammatory syndrome in children and implications for related diseases such as Kawasaki syndrome.

The winter season of respiratory diseases is nearly here. Knowing how to manage community-acquired pneumonia is essential.

Initial results from the trial indicate it was well-tolerated and promoted a good immune response.

Long COVID remains a mystery, more than a year after the condition first arose. To find answers, the National Institutes of Health (NIH) has created a research initiative, awarding grants totaling roughly $470 million.

Taxpayers ultimately picking up the tab for those refusing the jab.